Primary Site >> Biliary tract Cancer
Gene >> RRM1
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. PMID: 18636187 |
Ref: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. PMID: 21163702 Ref: Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma. PMID: 21940346 |
Ref: The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. PMID: 22197904 |
Ref: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. PMID: 22760605 Ref: Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. PMID: 23710668 |
Ref: Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. PMID: 25032731 Ref: Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. PMID: 25664003 |
Ref: Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. PMID: 26374242 Ref: Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer. PMID: 26418006 |
Ref: DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study. PMID: 29113399 |